2226552-64-1

2226552-64-1 structure

Name: WSD0922
Chemical Name: WSD0922
CAS Number: 2226552-64-1
Molecular Formula: C₂₃H₂₁F₃N₄O₂
Molecular Weight: 442.43
Catalog: Signaling Pathways JAK/STAT Signaling EGFR
Create Date: 2021-11-02 17:48:01
Modify Date: 2024-01-03 19:23:36
WSD-0922 is a potent, selective, orally active, and BBB penetrable EGFR/EGFRVIII inhibitor. WSD-0922 is against EGFRm+ (EGFRvIII/Del19/L858R) with an IC50 of <10 nM. WSD0922 shows good safety profile and preclinical anti-tumor efficacy[1].

Name	WSD0922

Description	WSD-0922 is a potent, selective, orally active, and BBB penetrable EGFR/EGFRVIII inhibitor. WSD-0922 is against EGFRm+ (EGFRvIII/Del19/L858R) with an IC50 of <10 nM. WSD0922 shows good safety profile and preclinical anti-tumor efficacy[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
Target	IC50: EGFRm+ (EGFRvIII/Del19/L858R)[1]
In Vivo	WSD0922 treatment results in tumor regression on cetuximab resistant PDX model of HNSCC. WSD0922 demonstrates remarkable tumor regression in 3 PDX models (platinum sensitive/insensitive/EGFRm+). WSD0922 is well tolerated in GLP tox at dose ~10x clinical equivalent dose.[1]
References	[1]. Wei Zhong, et al. Abstract 1326: WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor. Experimental and Molecular Therapeutics.

Molecular Formula	C₂₃H₂₁F₃N₄O₂
Molecular Weight	442.43